Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation
and immune modulation. Pharmacol Ther. 2004;103(2):147-166.
Majumder M, Xin X, Liu L, Girish GV, Lala PK. Prostaglandin E2 receptor EP4 as the common target on cancer
cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Cancer Sci. 2014;105(9):1142-1151.
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by
inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507-4513.
Holt D, Ma X, Kundu N, Fulton A. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily
through the PGE2 receptor EP4. Cancer Immunol Immunother. 2011;60(11):1577-1586.
Chou JP, Ramirez CM, Ryba DM, Koduri MP, Effros RB. Prostaglandin E2 promotes features of replicative
senescence in chronically activated human CD8+ T cells. PLoS One. 2014;9(6):e99432.
Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human
dendritic cell migration and exerts its effect via EP2 and EP4 receptors. The Journal of Immunology.
2006;176(2):966-73.
Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188(1):21-28.
Rong Y, Yuan CH, Qu Z, et al. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells
by releasing PGE2. Sci Rep. 2016;6:23824. doi:10.1038/srep23824.
Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2
redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.
Blood. 2011;118(20):5498-5505.
Miao J, Lu X, Hu Y, et al. Prostaglandin E and PD-1 mediated inhibition of antitumor CTL responses in the
human tumor microenvironment. Oncotarget. 2017;8(52):89802-89810.